{
    "id": 18862,
    "cites": 56,
    "cited_by": 0,
    "reference": [
        "Acemoglu, D. and J. Linn (2004). \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Quarterly Journal of Economics 119: 1049\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1090.",
        "Anderson, O. W., P. Collette, and J. J. Feldman. (1960) Expenditure Patterns for Personal Health Services, 1953 and 1958: Nationwide Survey. New York: Health Information Foundation.",
        "Ault, Kevin A. (2007) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Human Papillomavirus Vaccines and the Potential for Cross-protection Between Related HPV Types,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Gynecologic Oncology 107: S31\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009cS33.",
        "Australian Government Department of Health and Ageing. (2009) Guidelines for Deeds of Agreement for Pharmaceutical Benefits Scheme (Version 1.3). Canberra, Australia.",
        "Barder, O., M. Kremer, and R. Levine. (2005) Making Markets for Vaccines: Ideas to Action. Center for Global Development.",
        "Blanchflower, D. G. and A. J. Oswald. (2004) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Well-Being Over Time in Britain and the USA,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Public Economics 88: 1359\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1386.",
        "Boulier, B. (2006) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093A Shot in the Dark: Uncertainty and Vaccine Demand and Supply,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d George Washington University working paper.",
        "Centers for Disease Control. (2005) National Health and Examination Survey (NHANES) 2003\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c2004.",
        "Washington, D.C. Centers for Disease Control. (2006a) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Cases of HIV Infection and AIDS in the United States, 2004,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d HIV/AIDS SurveillanceReport, vol. 16. Table 8: \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Estimated Numbers of Persons Living with HIV/AIDS, by Year and Selected Characteristics, 2001-2004\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009d35 Areas with Confidential Name-Based HIV Infection Reporting\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d downloaded March 25, 2006 from www.cdc.gov/hiv/topics/surveillance/resources/-reports/2004report/default.htm.",
        "Centers for Disease Control. (2006b) HIV Prevalence Trends in Selected Populations in the United States: Results from National Serosurveillance,1993\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1997. Table 3: \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093HIV Prevalence Among Injection Drug Users Entering Drug Treatment Centers, by Metropolitan Area and Sex, 1993\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1997\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d downloaded April 14, 2006 from www.cdc.gov/hiv/pubs/hivprevalence/selected.htm.",
        "Centers for Disease Control. (2009) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Vaccines & Preventable Diseases: List of Vaccines Used in United States,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d downloaded October 10, 2009 from www.cdc.gov/vaccines/vpd-vac/vaccines-list.htm.",
        "Clay, K. B., D. S. Sibley, and P. Srinagesh. (1992) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Ex Post vs. Ex Ante Pricing: Optional Calling Plans and Tapered Tariffs,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Regulatory Economics 4: 115\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c138.",
        "Coase, R. J. (1972) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Durability and Monopoly,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Law and Economics 15: 143\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c149.",
        "Corey, E. J., L. K\u00c3\u0083\u00c2\u00bcrti, and B. Czak\u00c3\u0083\u00c2\u00b3. (2007) Molecules and Medicine. Hoboken: Wiley.",
        "Courty, P. (2003) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Ticket Pricing Under Demand Uncertainty,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Law and Economics 46: 627\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c 652.",
        "Euerle, B. and P. H. Chandrasekar. (2012) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Syphilis,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d in B. A. Cunha, ed., Medscape Reference. Accessed August 27, 2012 from emedicine.medscape.com/article/229461.",
        "Fey Cortez, Michelle and Simeon Bennett. (2011) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Gilead HIV Breakthrough of the Year Stymied by $12,000 Cost, Side Effects,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Bloomberg News, Feb. 28. Downloaded December 29, 2012 from www.bloomberg.com/news/2011-02-28/gilead-s-12-000-a-year-hiv-prevention-pill-fails-to-win -physician-support.html Francis, P. J. (1997) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Dynamic Epidemiology and the Market for Vaccinations,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Public Economics 63: 383-406.",
        "Finkelstein, A. (2004). \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Static and Dynamic Effect of Health Policy: Evidence from the Vaccine Industry,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Quarterly Journal of Economics 119: 527\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c564.",
        "Geoffard, P.-Y. and T. Philipson. (1997) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Disease Eradication: Public vs. Private Vaccination,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review 87: 222-230.",
        "Gersovitz, M. (2003) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Births, Recoveries, Vaccinations, and Externalities,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d in R. Arnott, ed., Economics for an Imperfect World: Essays in Honor of Joseph E. Stiglitz, 469\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c483.",
        "Gersovitz, M. and J. S. Hammer. (2005) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Tax/Subsidy Policy Toward Vector-Borne Infectious Diseases,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Public Economics 89: 647\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c674.",
        "Getzen, T. E. (2000) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Health care is an Individual Necessity and a National Luxury: Applying Multilevel Decision Models to the Analysis of Health Care Expenditures,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics 19: 259\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c270.",
        "Grady, D. (2012) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093F.D.A. Advisory Panel Back Preventive Use of H.I.V. Drug,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d New York Times, May 11: A1.",
        "Greenwood, D. (2008) Antimicrobial Drugs: Chronicle of a Twentieth Century Medical Triumph. Oxford: Oxford University Press.",
        "Harpavat, S. and S. Nissim. (2001) MicroCards: Review Cards for Medical Students. Philadelphia: Lippincott Williams & Wilkins.",
        "Hernandez, B. Y., et al. (2008) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Transmission of Human Papillomavirus in Heterosexual Couples,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Emerging Infectious Diseases 14: 888\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c894.",
        "Howard, Robin S. (2005) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Poliomyelitis and the Postpolio Syndrome,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d British Medical Journal 330: 1314\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c 1318.",
        "Immunization Action Coalition. (2009) Print Materials by Diseases and Vaccines downloaded October 10, 2009 from www.immunize.org/printmaterials/dis_tet.asp.",
        "Kaplan, E. H. (1990) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Modeling HIV Infectivity: Must Sex Acts Be Counted?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Acquired Immune Deficiency Syndromes 3: 55\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c61.",
        "Kessing, S. G. and R. Nuscheler. (2006) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Monopoly Pricing with Negative Network Effects: The Case of Vaccines,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d European Economic Review 50: 1061\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1069.",
        "Klein, B., R. A. Crawford, and A. A. Alchian. (1978) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Vertical Integration, Appropriable Rents, and the Competitive Contracting Process,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Law and Economics 21: 297\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c326.",
        "Kremer, M. and R. Glennerster. (2004) Strong Medicine: Creating Incentives for PharmaceuticalResearch on Neglected Diseases. Princeton: Princeton University Press.",
        "Kremer, M., C. M. Snyder, and H. Williams. (2012) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Vaccines: Integrated Economic and Epidemiological Models,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d mimeo, Harvard University.",
        "Lau, Brandyn D., Brian L. Pinto, David R. Thiemann, and Christoph U. Lehmann. (2011) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Budget Impact Analysis of Conversion from Intravenous to Oral Medication When Clinically Eligible for Oral Intake,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Clinical Therapeutics 33: 1792\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1796.",
        "Lewis, T. R. and D. E. M. Sappington. (1994) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Supplying Information to Facilitate Price Discrimination,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d International Economic Review 35: 309\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c327.",
        "Malueg, D. A. (1994) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Monopoly Output and Welfare: The Role of Curvature of the Demand Function,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Economic Education 25: 235\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c250.",
        "Maleug, D. A. and C. M. Snyder (2006) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Bounding the Relative Profitability of Price Discrimination,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d International Journal of Industrial Organization 24: 995-1011.",
        "Mandell, G. L., J. E. Bennett, and R. Dolin. (2009) Principles and Practice of Infectious Diseases seventh edition. Philadelphia: Elsevier Churchill Livingstone.",
        "Miravete, E. (1996) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Screening Consumers Through Alternative Pricing Mechanisms,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Regulatory Economics 9: 111\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c132.",
        "Morbidity and Mortality Weekly Report. (various years) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Summary of Notifiable Diseases, United States,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Centers for Disease Control and Prevention, downloaded December 20, 2009 from www.cdc.gov/-mmwr/mmwr_nd/index.html Mueller, Steffen, Eckard Wimmer, and Jeronimo Cello. (2005) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Poliovirus and Poliomyelitis: A Tale of Guts, Brains, and an Accidental Event,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Virus Research 111: 175\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c193.",
        "National Cancer Institute. (2009) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093BRCA1 and BRCA2: Cancer Risk and Genetic Testing,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d National Cancer Institute Fact Sheet. Retrieved August 16, 2012, from www.cancer.gov/cancertopics/factsheet/-Risk/BRCA.",
        "National Network for Immunization Information. (2009) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Vaccine Information,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d downloaded October 10, 2009 from www.immunizationinfo.org/vaccineInfo/index.cfm.",
        "Newell, R., A. Jaffee, and R. N. Stavins. (1999) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Induced Innovation Hypothesis and Energy-Saving Technological Change,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Quarterly Journal of Economics 114: 907\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c940.",
        "Newhouse, J. P. (1977) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Medical Care Expenditure: A Cross-National Survey,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Human Resources 12: 115\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c125.",
        "Nowsheen, S., et al. (2012) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093ER2 Overexpression Renders Human Breast Cancers Sensitive to PARP Inhibition Independently of Any Defect in Homologous Recombination DNA Repair,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Cancer Research 72: 4796\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c4806.",
        "Oster, E., I. Shoulson, K. Quaid, and E. R. Dorsey. (2010) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Genetic Adverse Selection: Evidence from Long-Term Care Insurance and Huntington Disease,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Public Economics 94: 1041\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1050.",
        "Pecorino, P. (2002) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Should the US Allow Prescription Drug Reimports from Canada?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics 21: 699\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c708.",
        "Rockstroh, J. K., et al. (1995) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Male-to-Female Transmission of HIV in a Cohort of Hemophiliacs\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009d Frequency, Risk Factors and Effect of Sexual Counseling,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Infection 23: 29\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c32.",
        "Rosenberg, E. (1999) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Drug Makers Shy from Work on AIDS Vaccine,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d San Francisco Examiner. March 16.",
        "Snyder, C. M., W. Begor, and E. R. Berndt. (2011) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Economic Perspectives on the Advance Market Commitment for Pneumococcal Vaccines,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Affairs 30: 1508\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1517.",
        "Stole, L. A. and J. Zwiebel. (1996) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Organizational Design and Technology Choice under Intrafirm Bargaining, \u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review 86: 195\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c222.",
        "Thomas, P. (2002) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Economics of Vaccines,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Harvard Medical International (HMI) World. September /October.",
        "UNAIDS. (2000) Epidemiological Fact Sheets by Country.",
        "UNAIDS. (2004) USA: Epidemiological Fact Sheets on HIV/AIDS and Sexually-Transmitted Infections.",
        "U.S. Food and Drug Administration. (2009) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Complete List of Vaccines Licensed for Immunization and Distribution in the US,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d downloaded October 10, 2009 from www.fda.gov/BiologicsBloodVaccines/-Vaccines/ApprovedProducts/ucm093833.htm.",
        "World Bank. (2000) World Development Indicators 2000. Washington, DC."
    ]
}